Genmab — Juni 2024
-
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT
▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer https://www.globenewswire.com/news-release/2024/05/31/2891769/0/en/Johnson-Johnson-submits-application-to-the-European-Medicines-Agency-seeking-approval-of-subcutaneous-formulation-of-RYBREVANT-amivantamab-for-the-treatment-of-patients-with-EGFR-m.html -
Investigational Acasunlimab (DuoBody
-PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) https://ir.genmab.com/news-releases/news-release-details/investigational-acasunlimab-duobodyr-pd-l1x4-1bb-combination -
Det ser da godt ud ? https://twitter.com/onco_park/status/1796947082323910739
-
Genmab and BioNTechs Revolutionary Bispecific Antibody Shows Promising Results https://csimarket.com/news/genmab-and-biontech-s-revolutionary-bispecific-antibody-shows-promising-results-i2024-06-01164271
-
Thanks E L. Very positive article about 1046. No mentioning of livertox. Maybe we can regain something on Monday!
-
Combining acasunlimab with pembrolizumab showed improved efficacy and safety when pembrolizumab was administered with a 6-week dosing regimen compared to a 3-week regimen. Interestingly, liver-related events were also less frequent with the 6-week https://x.com/onco_park/status/1796947082323910739?s=61&t=Ry4q9LC1jDgQzC__0QIEPg
pembrolizumab dosing. -
RYBREVANT
(amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazertinib-is-the-only-chemotherapy-free-regimen-showing-longer-progression-free-survival-versus-osimertinib-in-first-line-treatment-of-patients-with-high-risk-egfr-mutated-non-small-c -
Lorlatinib ser ud til at være en væsentlig konkurrent https://www.bt.dk/sundhed/forskere-begejstrede-ny-behandling-mod-lungekraeft-kan-vaere-paa-vej
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind